Company Filing History:

14 out of 281

Santen Pharmaceutical Co., Ltd.

Kanegafuchi Kagaku Kogyo Kabushiki Kaisha

patents

Years Active: 1996-2015

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8975256 - 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity (2015-03-10),

2. 8664221 - Method for treating an inflammatory disease by administering a 1,2,3,4- tetrahydroquinoxaline compound containing a phenyl group having a sulfonic acid ester structure introduced therein as a substituent (2014-03-04),

3. 8580784 - Method for treating a disease related to the glucocorticoid receptor (2013-11-12),

4. 8569493 - Method for treating a homeostasis-related disease or glaucoma by administering a 1,2,3,4-tetrahyroquinoxaline compound (2013-10-29),

5. 8563551 - Method for preventing or treating a disease related to the glucocorticoid receptor (2013-10-22),

6. 8551991 - 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity (2013-10-08),

7. 8440660 - Method for treating a disease related to the glucocorticoid receptor (2013-05-14),

8. 8426406 - Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group (2013-04-23),

9. 8420635 - Method for preventing or treating a glucocorticoid receptor-related disease (2013-04-16),

10. 8193187 - 1,2,3,4-tetrahydroquinoxaline compound with a phenyl group substituent having a sulfonic acid ester structure or a sulfonic acid amide structure introduced therein and having glucocorticoid receptor-binding activity (2012-06-05),

11. 8017775 - 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity (2011-09-13),

12. 8008498 - 1,2-dihydroquinoline derivative having substituted phenylamino lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

13. 8008497 - 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

14. 8008496 - 1,2-dihydroquinoline derivative having substituted phenylchalcogeno lower alkyl group and ester-introduced phenyl group as substituents (2011-08-30),

15. 7105602 - Processing aid for thermoplastic resin and thermoplastic resin composition containing the same (2006-09-12),

Title: **Inventor Toshiyuki Mori: Innovations in Therapeutic Compounds**

Introduction

Toshiyuki Mori is a notable inventor hailing from Ikoma, Japan, with a remarkable portfolio of 14 patents to his name. His contributions primarily focus on the development of innovative compounds aimed at treating inflammatory diseases. Through his work, Mori has been able to push the boundaries of pharmacological research, providing new avenues for therapeutic applications.

Latest Patents

Among his latest patents, Mori has developed 1,2,3,4-tetrahydroquinoxaline compounds with glucocorticoid receptor binding activity. These compounds are designed to target inflammatory conditions effectively. The nuances of his latest patents involve complex chemical structures, where substituents like halogens, alkyls, and aryl groups play significant roles in their activity. Particularly, his method for treating inflammatory diseases includes utilizing a 1,2,3,4-tetrahydroquinoxaline compound that features a phenyl group with a sulfonic acid ester structure, thereby representing a significant advancement in therapeutic compounds for managing various diseases.

Career Highlights

Mori has dedicated his career to pharmaceutical innovation, currently working at Santen Pharmaceutical Co., Ltd. His position allows him to explore and develop new therapeutic agents, contributing significantly to the field of medicine with his focus on glucocorticoid receptor agonists. His inventions are particularly groundbreaking in the area of inflammatory bone, joint diseases, and inflammatory ophthalmic diseases, proving useful for conditions traditionally treated with steroids.

Collaborations

Throughout his career, Toshiyuki Mori has worked alongside talented individuals like Mamoru Matsuda and Masatomo Kato. These collaborations have enabled him to enhance his research and development efforts, fostering a culture of innovation and advancing the scientific understanding of the compounds he develops.

Conclusion

In conclusion, Toshiyuki Mori stands out as a significant figure in the realm of medicinal chemistry and pharmacology. With 14 patents under his belt and a deep-seated commitment to addressing inflammatory diseases, Mori's work exemplifies the potency of targeted therapeutic research. His ingenious approaches serve not only to innovate but also to pave the way for potential breakthroughs in treating various medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com